Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 8

1.

A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease.

Macmillan ML, Couriel D, Weisdorf DJ, Schwab G, Havrilla N, Fleming TR, Huang S, Roskos L, Slavin S, Shadduck RK, Dipersio J, Territo M, Pavletic S, Linker C, Heslop HE, Deeg HJ, Blazar BR.

Blood. 2007 Mar 15;109(6):2657-62.

2.

ATG plus corticosteroid therapy for acute graft-versus-host disease: predictors of response and survival.

Dugan MJ, DeFor TE, Steinbuch M, Filipovich AH, Weisdorf DJ.

Ann Hematol. 1997 Jul-Aug;75(1-2):41-6. Review.

PMID:
9322682
3.

Monoclonal antibodies for the prevention and treatment of graft-versus-host disease.

Bruner RJ, Farag SS.

Semin Oncol. 2003 Aug;30(4):509-19. Review.

PMID:
12939720
4.

Monoclonal antibodies in the treatment of steroid-resistant acute graft-versus-host disease.

Tse JC, Moore TB.

Pharmacotherapy. 1998 Sep-Oct;18(5):988-1000. Review.

PMID:
9758310
5.

Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin.

Remberger M, Aschan J, Barkholt L, Tollemar J, Ringdén O.

Clin Transplant. 2001 Jun;15(3):147-53. Review.

PMID:
11389703
6.

[Role of monoclonal antibodies in the treatment of acute graft versus host disease].

Bay JO, Cabrespine A, Peffault de Latour R.

Bull Cancer. 2007 Jan;94(1):33-41. Review. French.

8.

Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease.

Antin JH, Chen AR, Couriel DR, Ho VT, Nash RA, Weisdorf D.

Biol Blood Marrow Transplant. 2004 Oct;10(10):655-68. Review. No abstract available.

Items per page

Supplemental Content

Support Center